Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01866930 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 3
- Development phase
- 453
- Enrollment target
NCT01866930 is a Phase 3 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 453 participants.
The verdict
NCT01866930, a Phase 3 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 453 participants
- Enrollment target
Study Summary
To evaluate Sustained Virologic Response at post treatment Week 12 (SVR12)following treatment with Lambda/RBV/DCV in chronic HCV GT-1, -2, -3 or -4 subjects co-infected with HIV-1
Interventions
- DRUG Daclatasvir (DCV)
- BIOLOGICAL Pegylated Interferon Lambda-1a
- DRUG Ribasphere (RBV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 453 participants |
| Start Date | 2013-07-11 |
| Est. Completion | 2015-08-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01866930
The ClinicalTrials.gov registry entry for NCT01866930 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 453 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Daclatasvir (DCV) is the first listed.
NCT01866930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01866930 about?
NCT01866930 is a clinical study titled "Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV". To evaluate Sustained Virologic Response at post treatment Week 12 (SVR12)following treatment with Lambda/RBV/DCV in chronic HCV GT-1, -2, -3 or -4 subjects co-infected with HIV-1
What is the current status of trial NCT01866930?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 453 participants. The study started on 2013-07-11. Estimated completion is 2015-08-27.
What interventions are being tested in trial NCT01866930?
The interventions under investigation include: Daclatasvir (DCV) (DRUG), Pegylated Interferon Lambda-1a (BIOLOGICAL), Ribasphere (RBV) (DRUG).
Who is sponsoring clinical trial NCT01866930?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.